U.S. Construction Stock News

O’Reilly Automotive recently completed a buyback tranche, repurchasing 9,404,000 shares for US$857.19 million between April and August 2025, finalizing a very large buyback program that started in 2011. This substantial completion of the repurchase initiative signals management’s ongoing confidence in the company’s long-term performance and their commitment to returning capital to shareholders. With the buyback program now complete, we’ll consider how returning capital to shareholders could...

If you are trying to make sense of Insulet’s recent run, you are not alone. Whether you already hold shares or are weighing a new buy, it is tough to look away from a stock that has powered up nearly 30% year-to-date and delivered a whopping 79% total return over the past year. The buzz makes sense, with Insulet’s sales up by more than 14% and annual net income growth topping 23%. All of this comes with the shares closing recently at $333, just a modest 5.7% below the average analyst price...

If you held shares of Uranium Energy (UEC) over the past month, you probably noticed your portfolio got a boost. The stock climbed nearly 17% in that period. There has been no game-changing headline or sudden corporate announcement to spark this run, but that kind of momentum is enough to get any investor wondering if the market sees value others have missed, or if this is just another blip in a volatile sector. This move fits into a bigger picture of rising momentum for Uranium Energy,...

On August 12, 2025, Insmed Incorporated announced that the U.S. FDA approved BRINSUPRI (brensocatib), the first and only FDA-approved oral therapy for non-cystic fibrosis bronchiectasis in adults and children 12 years and older, with Maxor Specialty Pharmacy later selected as a limited distribution provider. This approval not only introduces a first-in-class treatment for an underserved patient population but also positions Insmed to potentially establish a new standard of care for...

If you have been following Cigna Group (CI) lately, you’ve probably noticed the stock’s share price drifting higher. The increase has been subtle, but just enough to catch the eye. There hasn’t been a single major announcement sparking this move; however, with a share price now sitting above $300 and a year-to-date gain over 10%, many investors are wondering whether the recent momentum is revealing something about sentiment or simply reflects the normal ebb and flow of a maturing company...

Something caught your eye with Northern Trust (NTRS) today? While there is no breaking development triggering an abrupt move, this recent bump in the share price might have some investors wondering if market optimism is building or simply reacting to shifting expectations. In moments like this, it pays to look under the hood and see if this near-term momentum matches up with the underlying business or if we are just seeing market noise. Over the past year, Northern Trust stock has recorded a...

W. R. Berkley (WRB) just unveiled Berkley Edge, a brand-new operation dedicated to serving small and mid-sized businesses with professional liability and casualty insurance, especially in cases that are tough to underwrite. This move, along with the appointment of industry veteran Jamie Secor to lead the venture, is a clear statement about where the company sees opportunity: in specialty insurance, targeting risks that many competitors pass by. For investors, this expansion is worth a closer...

If you are sitting on the fence about what to do with BWX Technologies stock right now, you are definitely not alone. With its impressive run over the last year, climbing more than 63%, BWXT has landed squarely on the radar for many investors searching for growth stories and stable plays alike. The stock’s gains are even more eye-catching when you zoom out, doubling over the last three and five years, and surging more than 51% in just the past three months. These outsized returns tell a story...

It is not every day that Novo Nordisk (NYSE:NVO) catches eyes for all the wrong reasons, but this week’s slide has certainly prompted investors to pause. The stock dropped by roughly 0.9% in the past day and now sits a staggering 58% below its level a year ago. While there is no single dramatic event driving these shifts, the persistent decline has many wondering whether this signals deeper issues or simply reflects changing market sentiment around the pharmaceutical sector. Looking at a...

If you have been tracking Eaton (ETN) lately, you probably noticed some movement in its stock price that might give investors pause. Shares have dipped by about 7% over the past month, without any single significant news event capturing headlines. Sometimes, it is exactly these kinds of shifts that leave people wondering whether the market is adjusting to new information behind the scenes, perhaps related to anticipation around future growth or changing risk perceptions. Looking at the bigger...

If you have D.R. Horton in your portfolio or have been watching from the sidelines wondering if now is the time to buy, you are not alone. The stock has been anything but boring lately. Over the past month, shares are up roughly 24.5%. Looking back three months, that gain stretches to more than 37%. Even after accounting for a small dip over the last week, the recent surge shows investors are betting on growth, or at least a shift toward renewed optimism around homebuilders. D.R. Horton has...

Suburban Propane Partners reported its third-quarter and nine-month earnings results, showing third-quarter revenue of US$260.15 million and a net loss of US$14.84 million, while nine-month revenue reached US$1.22 billion with net income of US$141.71 million. Despite year-over-year improvements in revenue and net results, concerns remain about the company's high debt, repeated distribution cuts, and use of ATM equity programs. Next, we will examine how these debt and distribution concerns...

NasdaqGS:NVCR 1 Year Share Price vs Fair Value Explore NovoCure's Fair Values from the Community and select yours...

If you have been keeping an eye on Motorola Solutions stock, you know it rarely strays far from investors' radar. Maybe you are wondering if this run can keep going or if it is time to lock in gains. After all, in the last thirty days, MSI's share price has climbed nearly 10%, and over the past year, it has delivered an impressive 9.6% total return. Even more eye-catching is that the stock has more than doubled investors’ money if you stretch the timeline back five years. This is not too...

On August 20, 2025, Huntington Ingalls Industries (HII) announced that its Mission Technologies division is among the companies awarded a multiple award contract, with a ceiling of US$267 million, to provide training products and services to enhance U.S. Navy fleet readiness. This award enables HII to compete for substantial task orders in supporting the Navy’s professional development, including delivering digital curriculum and on-demand learning solutions crucial for adapting to evolving...

Thinking about what to do with fuboTV stock? You are not alone. Investors have watched this streaming-focused player deliver some rollercoaster returns lately. Over just the past year, FUBO rocketed up more than 66% in total return. Zoom out, though, and you will see a stock that has lost ground over three and five years. This underscores just how volatile the journey has been. Recently, after some short-term pop, the stock has pulled back a bit, reminding everyone that big price swings are...

NYSE:KEYS 1 Year Share Price vs Fair Value Explore Keysight Technologies's Fair Values from the Community and select...

Humana (HUM) has been under the spotlight recently after a quick rebound in its stock price over the past month. Although there has not been a single headline-grabbing event to explain the momentum, the move is raising eyebrows for investors who may be considering whether to participate in this rally or wait on the sidelines. When a large healthcare company’s shares gain nearly 30% in a single month without dramatic news, it can signal a shift in market sentiment. This may reflect an...

If you’re wondering what to do with Collegium Pharmaceutical (COLL) in light of their latest earnings report, you’re not alone. The company just posted its second quarter numbers, revealing a drop in earnings compared to last year, but also surprised many by raising its full year revenue guidance. In addition, Collegium provided an update on its aggressive share buyback program, which could speak volumes about management’s confidence or at least their current preferred use of cash. These...

Thinking about what to do with DoorDash stock right now? You are definitely not alone. Whether you have been riding the wave for the past year or are just peeking at the ticker for the first time, there is no denying that DoorDash has been on the move. In the past year, the stock has nearly doubled, delivering a massive 88% total return. The past three months alone have seen a 21% jump, which is remarkable momentum for a company that is already a household name in food delivery. The energy...

Earlier this month, Establishment Labs Holdings raised its 2025 revenue guidance to a range of US$208 million to US$212 million and reported second-quarter sales of US$51.3 million, up from US$44.12 million a year prior. An interesting aspect is the company's forecast of at least US$40 million in US Motiva revenue for the year, marking the growing importance of its US operations in total sales. We'll explore how the stronger full-year revenue outlook and US Motiva momentum could influence...

If you’ve been tracking Brookfield Business (NYSE:BBUC), the recent renewal of its normal course issuer bids for both limited partnership units and class A exchangeable subordinate voting shares probably caught your eye. Management is sending a clear message about their confidence in the firm’s intrinsic value, especially with buyback programs often interpreted as a commitment to shareholder returns. The regulatory filings released alongside this move suggest Brookfield is focused on capital...

ServiceNow (NYSE:NOW) recently caught investor attention after shares bounced nearly 4% in the past week, shrugging off some month-long pressure that saw the stock dip about 7%. There has been no single headline catalyst driving this latest move. With ServiceNow’s valuation already a subject of debate, even modest volatility prompts a closer look. When a tech leader like this changes direction, it naturally raises questions about what could be next for the price and whether this is a good...

NasdaqCM:UBXG 1 Year Share Price vs Fair Value Explore U-BX Technology's Fair Values from the Community and select...